Posted 28th November 2018 by Jane Williams
It was a pleasure to have Dirk Gevers involved in our Microbiome Futures project earlier this year. In the following opinion piece, Dirk reflects on the outcomes that went on to be published in Nature Biotechnology.
The original article can be found on Biovox and is republished here with kind permission.
Posted 9th November 2018 by Jane Williams
In May of this year, Nature Biotechnology and Global Engage convened a panel of leaders in the microbiome field that included CEOs and CSOs of several microbiome companies, representatives from big pharmas working in the space, and top academics from the New York area and beyond to discuss the current state of the art in human microbiome research and its translation into therapies.
Posted 3rd May 2018 by Jane Williams
The opportunity afforded by the microbiome for developing therapeutic and wellness products is matched only by the formidable task of unraveling the science of the microbiome in the first place. Microbiome research is transitioning from a descriptive to a more mechanistic science, and progress in understanding mechanisms that underpin microbiome biology is likely to result in a surge of interest in this space on the part of the biotech, pharma and investor communities.
Posted 5th April 2018 by Jane Williams
Most microbiome research to date has focused on the bacterial gut microbiome, and yet microbiomes are comprised of a wide array of microbes – from viruses and archaea to protozoa and yeasts – and colonize nearly every human body site – from the skin and lungs to the urogenital system and breast milk.
Posted 15th March 2018 by Jane Williams
‘The most that can be expected from any model is that it can supply a useful approximation to reality: All models are wrong; some models are useful.’
This aphorism, simply articulated here by prominent British statistician George Box, gets to the crux of the dilemma we face when considering animal models for the study of human microbiome dynamics and mechanisms.
Posted 1st March 2018 by Jane Williams
Translation. When we hear this word, it may evoke feelings of excitement, adventure and possibility that come with learning different languages or travelling to a foreign country. For scientists, ‘translation’ also suggests moving research findings from the laboratory into clinical practice. Just as words are translated, so too are research findings.
Posted 15th February 2018 by Jane Williams
With 2017 now in the rear-mirror, it is a good time to assess the investment landscape in the microbiome space and try to identify relevant trends indicative of where microbiome science and the industry might be headed next. To do this I contacted Matt Martin, Microbiome Innovation and Ventures Lead at the University of Chicago. Matt has been analyzing the space for some time now, and in collaboration with Michael Lohmeier, a student at the Tepper School of Business, Carnegie Mellon University, has kept a tab on companies and investors alike.
Posted 11th January 2018 by Jane Williams
Microbiome-based interventions, whether therapeutic or prophylactic, come in a broad spectrum of modalities, a consequence of the complexity of and possibilities afforded by the microbiome.